Get the Stockscreener App
9.61
1.94%
-0.19
Pre-market:
9.59
-0.02
-0.21%
Atara Biotherapeutics Inc stock is traded at $9.61, with a volume of 182.34K.
It is down -1.94% in the last 24 hours and up +91.82% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
See More
Previous Close:
$9.80
Open:
$9.64
24h Volume:
182.34K
Relative Volume:
0.13
Market Cap:
$86.59M
Revenue:
$23.14M
Net Income/Loss:
$-9.47M
P/E Ratio:
-10.89
EPS:
-0.8827
Net Cash Flow:
$-25.88M
1W Performance:
+2.13%
1M Performance:
+91.82%
6M Performance:
-35.33%
1Y Performance:
+34.59%
1-Day Range:
$9.15
$10.08
1-Week Range:
$8.88
$10.08
52-Week Range:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
9.61 | 88.30M | 23.14M | -9.47M | -25.88M | -0.8827 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. LawsuitATRA - Morningstar
ATRA stock shoots up 82% in a month: Here's what you should know - MSN
ATRA DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Atara Biotherapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - New Castle News
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - New Castle News
ATARA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
ATRARA (NASDAQ:ATRA) DEADLINE MAY 22nd: Bragar Eagel & - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know - The Globe and Mail
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara - GuruFocus
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - PR Newswire
Atara Biotherapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your RightsATRA - PR Newswire
Atara Biotherapeutics CAO sells $22,036 of company stock By Investing.com - Investing.com Canada
Atara Biotherapeutics CEO AnhCo Nguyen sells $47,844 in stock By Investing.com - Investing.com South Africa
Atara Biotherapeutics CEO AnhCo Nguyen sells $47,844 in stock - Investing.com
Atara (ATRA) CEO sells 5,241 shares in automatic tax sale - Stock Titan
Atara Biotherapeutics (ATRA) CAO sells 2,414 shares to cover RSU tax - Stock Titan
ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. ... - Caledonian Record
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages - GlobeNewswire
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Atara Biotherapeutics Raised to Hold From Sell by Freedom Broker - Moomoo
Atara Biotherapeutics Price Target Raised to $10.00/Share From $4.00 by Freedom Broker - Moomoo
ATRA UPCOMING DEADLINE : The Gross Law Firm Alerts Atara Biotherapeutics, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Class Action Litigation Filed by Pomerantz LLP for Investors of Atara Biotherapeutics, Inc. – ATRA - ACCESS Newswire
ATRA Upgraded by Freedom Broker -- Price Target Raised to $10 - GuruFocus
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, I - GuruFocus
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - lincolnjournal.com
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATARA DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, - GlobeNewswire
[144] Atara Biotherapeutics, Inc. SEC Filing - Stock Titan
Company (NASDAQ: ATRA) RSU Settlement and 2,104-Share Sale - Stock Titan
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) - GlobeNewswire
DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of - GlobeNewswire
Freedom Broker upgrades Atara Biotherapeutics stock rating on FDA meeting progress - Investing.com
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit ... - Caledonian Record
Class Action Litigation Filed by Pomerantz LLP Concerning Atara Biotherapeutics, Inc. – ATRA - ACCESS Newswire
Trading Systems Reacting to (ATRA) Volatility - Stock Traders Daily
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action ... - Caledonian Record
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of May 22, 2026ATRA - The Daily Tribune News
Redmile funds disclose 9.9% Atara Biotherapeutics (ATRA) stake via warrants cap - Stock Titan
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):